Researchers focused on Myotonic Dystrophy 1 heart problems are testing a novel approach to restore normal function.

The therapy, EPI-321, is intended to treat cases of facioscapulohumeral muscular dystrophy, a genetic neuromuscular disorder.

An 8-year-old northern Minnesota boy is one of the first in the country to receive a specific type of gene therapy treatment.

Emery-Dreifuss muscular dystrophy type 1, and multiple sclerosis. Before the FDA approved Nippon Shinyaku’s DMD drug Viltepso in 2020, Sarepta was the only company to market DMD drugs in the ...

Avidity Biosciences, Inc.’s RNA share price has surged by 11.33%, which has investors questioning if this is right time to sell.

Minnesota (WCCO) — An 8-year-old northern Minnesota boy is one of the first in the country to receive a specific type ... muscular dystrophy — a rare condition that affects 1 in 5,000 children ...